PCV25 THE ECONOMIC IMPACTS OF TROUGH: PEAK RATIO AND LIPOPHILICITY ON COST-EFFECTIVENESS OF ACE-INHIBITOR THERAPY FOR HYPERTENSION  by Keuffel, EL et al.
171Abstracts
assessing quality, using common endpoints at 6 months,
1, and 2 years, ﬁve trials on orlistat (120mg TID) and six
on sibutramine (10mg QD) were selected. Pooled esti-
mates of weighted mean difference (between placebo and
drug) in proportion of patients losing 10% or more of
body weight (the primary outcome) were derived. Life-
time health and economic beneﬁts of sustained 10%
weight loss for adults aged 35–64 years with mild (BMI 
27.5kg/m2), moderate (BMI 32.5kg/m2) and severe (BMI
37.5kg/m2) obesity from a recently published cost-of-
obesity model (Am J Public Health, 1999,89:1536) of 
the relationship between BMI, risks, and cost of ﬁve
obesity-related diseases (hypertension, hypercholes-
terolemia, diabetes, coronary heart disease, stroke) were
used. Using direct costs, CBA was performed with
weighted average savings (transformed to year 2001 US$)
by age, BMI, and proportion losing 10% or more of body
weight. Sensitivity analysis by varying the proportion of
patients sustaining 10% weight loss (+/-20%) and dis-
count rate was done.
RESULTS: Beneﬁt-cost ratios of orlistat and sibutramine
were less than one for the base-case analysis at 6 months,
1 year and 2 years. Best/worst-case beneﬁt-cost ratio (via
sensitivity analysis) of orlistat remained less than one,
while that of sibutramine was 1.8/1.2 at 1 year.
CONCLUSIONS: Unless the proportion of patients 
sustaining 10% weight-loss increases, neither orlistat nor
sibutramine would prove cost-beneﬁcial in formulary
coverage decisions.
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OBJECTIVE: While a “class effect” is often attributed to
ACE-Inhibitor (ACE-I) therapy in hypertension, phar-
macokinetic and pharmacodynamic differences exist
between agents for endpoints such as trough :peak ratio
and lipophilicity. Agents with these clinical advantages
may enable patients to more consistently achieve and
maintain low blood pressure (BP) than agents with lower
trough :peak ratios and poorer lipophilicity. This study
assessed the economic implications of these clinical 
beneﬁts in the management of hypertension. 
METHODS: A literature-based decision model was
developed to project the relative costs and effectiveness
over one year of four commonly prescribed ACE-Is
(benazepril, lisinopril, ramipril and quinapril) versus
trandolapril from the perspective of a typical managed
care plan (MCO) with 100,000 members, of whom 1,700
were projected to take ACE-Is for hypertension. Therapy
effectiveness was measured as the proportion of patients
achieving BP control. Controlled patients were assumed
to incur substantially lower non-drug costs ($599–
$1,048) than uncontrolled patients ($4,449–$17,751).
Drug costs reﬂected the price and actual dose taken based
on national prescription data. In the most conservative
scenario, all therapies were assumed to result in identical
levels of BP control (59%). In the least conservative sce-
nario, it was assumed that patients taking therapies with
either poorer lipophilicity or lower trough: peak ratios
would be less frequently controlled (38%).
RESULTS: Trandolapril saved between $48,000 to
$235,000 compared to other ACE-Is in the most conser-
vative scenario. In the least conservative scenario, the cost
of therapies with lower BP control increased signiﬁcantly
and exceeded that of trandolapril by $1.8 to $2.0 million.
CONCLUSIONS: In both scenarios, trandolapril saved
costs relative to comparator ACE-I therapies. These
savings were driven by trandolapril’s lower price and 
the clinical beneﬁts anticipated to result from its lower
trough :peak ratio and better lipophilicity. These beneﬁts
include more consistent BP control and reduced need for
multiple dosing.
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This study presents ﬁrst attempt in Russia to assess will-
ingness to pay for medication treatment.
OBJECTIVE: To obtain monetary valuation of beneﬁts
concerned with avoiding amputation in case of critical
limb ischemia in Russia. 
METHODS: 191 physicians and 137 health care man-
agers ﬁlled in the questionnaire about their willingness 
to pay for medication treatment for critical limb ischemia
with prostaglandin E1 if amputation rate decreases to
12% in comparison with 48% in present common prac-
tice. The probability of amputation was extracted from 
a retrospective analysis of the outcomes of managing 105
patients with critical limb ischemia in common practice
and a published follow-up study of 752 patients treated
with prostaglandin E1 at Moscow surgery center. The
respondents had to assess their maximum out-of-pocket
expenses and maximum possible expenses for national
health care system (NHCS). 
RESULTS: 22.8% of respondents could not give a mon-
etary value for the hypothetical situation. Median value
for out-of-pocket expenses was 30,000 roubles (about
1,000 USD$); the range 1,500–435,000 roubles for 
physicians and 15,000 roubles (500 USD); the range of
500–175,000 roubles for health care managers. Accord-
ing to physicians opinion, payment from the NHCS
should be 70 ± 30% of the named sum. Health care man-
agers answered that NHCS should cover about 80 ± 27%
of the expenses.
CONCLUSION: First experience of assessing willingness
to pay showed that health care managers in Russia are
